Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Rovin BH, Caster DJ, Cattran DC, Gibson KL, Hogan JJ, Moeller MJ, Roccatello D, Cheung M, Wheeler DC, Winkelmayer WC, Floege J; Conference Participants.

Kidney Int. 2019 Feb;95(2):281-295. doi: 10.1016/j.kint.2018.11.008.

PMID:
30665569
2.

Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Floege J, Barbour SJ, Cattran DC, Hogan JJ, Nachman PH, Tang SCW, Wetzels JFM, Cheung M, Wheeler DC, Winkelmayer WC, Rovin BH; Conference Participants.

Kidney Int. 2019 Feb;95(2):268-280. doi: 10.1016/j.kint.2018.10.018.

PMID:
30665568
3.

Integration of Genetic Testing and Pathology for the Diagnosis of Adults with FSGS.

Yao T, Udwan K, John R, Rana A, Haghighi A, Xu L, Hack S, Reich HN, Hladunewich MA, Cattran DC, Paterson AD, Pei Y, Barua M.

Clin J Am Soc Nephrol. 2019 Jan 15. pii: CJN.08750718. doi: 10.2215/CJN.08750718. [Epub ahead of print]

PMID:
30647093
4.

Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy.

Thompson A, Carroll K, A Inker L, Floege J, Perkovic V, Boyer-Suavet S, W Major R, I Schimpf J, Barratt J, Cattran DC, S Gillespie B, Kausz A, W Mercer A, Reich HN, H Rovin B, West M, Nachman PH.

Clin J Am Soc Nephrol. 2019 Mar 7;14(3):469-481. doi: 10.2215/CJN.08600718. Epub 2019 Jan 11.

PMID:
30635299
5.

Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study.

Selewski DT, Ambruzs JM, Appel GB, Bomback AS, Matar RB, Cai Y, Cattran DC, Chishti AS, D'Agati VD, D'Alessandri-Silva CJ, Gbadegesin RA, Hogan JJ, Iragorri S, Jennette JC, Julian BA, Khalid M, Lafayette RA, Liapis H, Lugani F, Mansfield SA, Mason S, Nachman PH, Nast CC, Nester CM, Noone DG, Novak J, O'Shaughnessy MM, Reich HN, Rheault MN, Rizk DV, Saha MK, Sanghani NS, Sperati CJ, Sreedharan R, Srivastava T, Swiatecka-Urban A, Twombley K, Vasylyeva TL, Weaver DJ, Yin H, Zee J, Falk RJ, Gharavi AG, Gillespie BW, Gipson DS, Greenbaum LA, Holzman LB, Kretzler M, Robinson BM, Smoyer WE, Flessner M, Guay-Woodford LM, Kiryluk K; CureGN Consortium.

Kidney Int Rep. 2018 Aug 3;3(6):1373-1384. doi: 10.1016/j.ekir.2018.07.021. eCollection 2018 Nov.

6.

Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group.

Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, Liu ZH, Roberts IS, Yuzawa Y, Zhang H, Feehally J; IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Conference Participants.

Kidney Int. 2017 May;91(5):1014-1021. doi: 10.1016/j.kint.2017.02.003. Epub 2017 Mar 22. Review.

7.

Membranous nephropathy: integrating basic science into improved clinical management.

Cattran DC, Brenchley PE.

Kidney Int. 2017 Mar;91(3):566-574. doi: 10.1016/j.kint.2016.09.048. Epub 2017 Jan 5. Review.

PMID:
28065518
8.

Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation.

Cosio FG, Cattran DC.

Kidney Int. 2017 Feb;91(2):304-314. doi: 10.1016/j.kint.2016.08.030. Epub 2016 Nov 10. Review.

PMID:
27837947
9.

Membranous Nephropathy: Quantifying Remission Duration on Outcome.

Cattran DC, Kim ED, Reich H, Hladunewich M, Kim SJ; Toronto Glomerulonephritis Registry group.

J Am Soc Nephrol. 2017 Mar;28(3):995-1003. doi: 10.1681/ASN.2015111262. Epub 2016 Oct 18.

10.

Toward quantitating the burden of glomerulonephritis in the United States.

Cattran DC.

Kidney Int. 2016 Oct;90(4):732-4. doi: 10.1016/j.kint.2016.06.004.

PMID:
27633866
11.

The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseases.

Hogan MC, Reich HN, Nelson PJ, Adler SG, Cattran DC, Appel GB, Gipson DS, Kretzler M, Troost JP, Lieske JC.

Kidney Int. 2016 Nov;90(5):1080-1089. doi: 10.1016/j.kint.2016.06.020. Epub 2016 Aug 12.

12.

Intensive glycemic control and the risk of end-stage renal disease: an ADVANCE in the management of diabetes?

Wyatt CM, Cattran DC.

Kidney Int. 2016 Jul;90(1):8-10. doi: 10.1016/j.kint.2016.05.002.

PMID:
27312437
13.

Patients with primary membranous nephropathy are at high risk of cardiovascular events.

Lee T, Derebail VK, Kshirsagar AV, Chung Y, Fine JP, Mahoney S, Poulton CJ, Lionaki S, Hogan SL, Falk RJ, Cattran DC, Hladunewich M, Reich HN, Nachman PH.

Kidney Int. 2016 May;89(5):1111-1118. doi: 10.1016/j.kint.2015.12.041. Epub 2016 Feb 26.

PMID:
26924046
14.

The MEST score provides earlier risk prediction in lgA nephropathy.

Barbour SJ, Espino-Hernandez G, Reich HN, Coppo R, Roberts IS, Feehally J, Herzenberg AM, Cattran DC; Oxford Derivation, North American Validation and VALIGA Consortia; Oxford Derivation North American Validation and VALIGA Consortia.

Kidney Int. 2016 Jan;89(1):167-75. doi: 10.1038/ki.2015.322.

PMID:
26759049
15.

Complete Remission in the Nephrotic Syndrome Study Network.

Gipson DS, Troost JP, Lafayette RA, Hladunewich MA, Trachtman H, Gadegbeku CA, Sedor JR, Holzman LB, Moxey-Mims MM, Perumal K, Kaskel FJ, Nelson PJ, Tuttle KR, Bagnasco SM, Hogan MC, Dell KM, Appel GB, Lieske JC, Ilori TO, Sethna CB, Fervenza FC, Hogan SL, Nachman PH, Rosenberg AZ, Greenbaum LA, Meyers KE, Hewitt SM, Choi MJ, Kopp JB, Zhdanova O, Hodgin JB, Johnstone DB, Adler SG, Avila-Casado C, Neu AM, Hingorani SR, Lemley KV, Nast CC, Brady TM, Barisoni-Thomas L, Fornoni A, Jennette JC, Cattran DC, Palmer MB, Gibson KL, Reich HN, Mokrzycki MH, Sambandam KK, Zilleruelo GE, Licht C, Sampson MG, Song P, Mariani LH, Kretzler M.

Clin J Am Soc Nephrol. 2016 Jan 7;11(1):81-9. doi: 10.2215/CJN.02560315. Epub 2015 Dec 10.

16.

Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN.

Sethi S, Haas M, Markowitz GS, D'Agati VD, Rennke HG, Jennette JC, Bajema IM, Alpers CE, Chang A, Cornell LD, Cosio FG, Fogo AB, Glassock RJ, Hariharan S, Kambham N, Lager DJ, Leung N, Mengel M, Nath KA, Roberts IS, Rovin BH, Seshan SV, Smith RJ, Walker PD, Winearls CG, Appel GB, Alexander MP, Cattran DC, Casado CA, Cook HT, De Vriese AS, Radhakrishnan J, Racusen LC, Ronco P, Fervenza FC.

J Am Soc Nephrol. 2016 May;27(5):1278-87. doi: 10.1681/ASN.2015060612. Epub 2015 Nov 13.

17.

Identifying the ideal metric of proteinuria as a predictor of renal outcome in idiopathic glomerulonephritis.

Barbour SJ, Cattran DC, Espino-Hernandez G, Hladunewich MA, Reich HN.

Kidney Int. 2015 Dec;88(6):1392-1401. doi: 10.1038/ki.2015.241. Epub 2015 Aug 19.

PMID:
26287314
18.

Integrative Genomics Identifies Novel Associations with APOL1 Risk Genotypes in Black NEPTUNE Subjects.

Sampson MG, Robertson CC, Martini S, Mariani LH, Lemley KV, Gillies CE, Otto EA, Kopp JB, Randolph A, Vega-Warner V, Eichinger F, Nair V, Gipson DS, Cattran DC, Johnstone DB, O'Toole JF, Bagnasco SM, Song PX, Barisoni L, Troost JP, Kretzler M, Sedor JR; Nephrotic Syndrome Study Network.

J Am Soc Nephrol. 2016 Mar;27(3):814-23. doi: 10.1681/ASN.2014111131. Epub 2015 Jul 6.

19.

A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).

Fervenza FC, Canetta PA, Barbour SJ, Lafayette RA, Rovin BH, Aslam N, Hladunewich MA, Irazabal MV, Sethi S, Gipson DS, Reich HN, Brenchley P, Kretzler M, Radhakrishnan J, Hebert LA, Gipson PE, Thomas LF, McCarthy ET, Appel GB, Jefferson JA, Eirin A, Lieske JC, Hogan MC, Greene EL, Dillon JJ, Leung N, Sedor JR, Rizk DV, Blumenthal SS, Lasic LB, Juncos LA, Green DF, Simon J, Sussman AN, Philibert D, Cattran DC; Mentor Consortium group.

Nephron. 2015;130(3):159-68. doi: 10.1159/000430849. Epub 2015 Jun 12.

PMID:
26087670
20.

Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy.

Thompson A, Cattran DC, Blank M, Nachman PH.

J Am Soc Nephrol. 2015 Dec;26(12):2930-7. doi: 10.1681/ASN.2015010091. Epub 2015 Jun 15.

21.

The (99m)Tc-DTPA urinary clearance method may be preferable to the plasma disappearance method for assessing glomerular filtration rate in diabetic nephropathy.

Huang SH, Eliasziw M, Spence JD, Filler G, Vezina WC, Churchill DN, Cattran DC, Richardson B, House AA.

Nephron Clin Pract. 2014;128(3-4):367-72. doi: 10.1159/000368901. Epub 2015 Jan 8.

PMID:
25571980
22.

The authors reply.

Dhaun N, Bellamy CO, Cattran DC, Kluth DC.

Kidney Int. 2014 Dec;86(6):1269. doi: 10.1038/ki.2014.278. No abstract available.

23.

The molecular phenotype of endocapillary proliferation: novel therapeutic targets for IgA nephropathy.

Hodgin JB, Berthier CC, John R, Grone E, Porubsky S, Gröne HJ, Herzenberg AM, Scholey JW, Hladunewich M, Cattran DC, Kretzler M, Reich HN.

PLoS One. 2014 Aug 18;9(8):e103413. doi: 10.1371/journal.pone.0103413. eCollection 2014.

24.

Utility of renal biopsy in the clinical management of renal disease.

Dhaun N, Bellamy CO, Cattran DC, Kluth DC.

Kidney Int. 2014 May;85(5):1039-48. doi: 10.1038/ki.2013.512. Epub 2014 Jan 8. Review. Erratum in: Kidney Int. 2014 Dec;86(6):1268.

25.

Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy.

Lee T, Biddle AK, Lionaki S, Derebail VK, Barbour SJ, Tannous S, Hladunewich MA, Hu Y, Poulton CJ, Mahoney SL, Charles Jennette J, Hogan SL, Falk RJ, Cattran DC, Reich HN, Nachman PH.

Kidney Int. 2014 Jun;85(6):1412-20. doi: 10.1038/ki.2013.476. Epub 2013 Dec 11.

26.

ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption.

Ashraf S, Gee HY, Woerner S, Xie LX, Vega-Warner V, Lovric S, Fang H, Song X, Cattran DC, Avila-Casado C, Paterson AD, Nitschké P, Bole-Feysot C, Cochat P, Esteve-Rudd J, Haberberger B, Allen SJ, Zhou W, Airik R, Otto EA, Barua M, Al-Hamed MH, Kari JA, Evans J, Bierzynska A, Saleem MA, Böckenhauer D, Kleta R, El Desoky S, Hacihamdioglu DO, Gok F, Washburn J, Wiggins RC, Choi M, Lifton RP, Levy S, Han Z, Salviati L, Prokisch H, Williams DS, Pollak M, Clarke CF, Pei Y, Antignac C, Hildebrandt F.

J Clin Invest. 2013 Dec;123(12):5179-89. doi: 10.1172/JCI69000. Epub 2013 Nov 25.

27.

Evaluation of the Oxford Classification of IgA nephropathy: a systematic review and meta-analysis.

Lv J, Shi S, Xu D, Zhang H, Troyanov S, Cattran DC, Wang H.

Am J Kidney Dis. 2013 Nov;62(5):891-9. doi: 10.1053/j.ajkd.2013.04.021. Epub 2013 Jun 29. Review.

PMID:
23820066
28.

Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease.

Barbour SJ, Cattran DC, Kim SJ, Levin A, Wald R, Hladunewich MA, Reich HN.

Kidney Int. 2013 Nov;84(5):1017-24. doi: 10.1038/ki.2013.210. Epub 2013 Jun 5. Erratum in: Kidney Int. 2015 Jan;87(1):242.

29.

A pilot study of reduced dose cyclosporine and corticosteroids to reduce new onset diabetes mellitus and acute rejection in kidney transplant recipients.

Cole EH, Prasad GV, Cardella CJ, Kim JS, Tinckam KJ, Cattran DC, Schiff JR, Landsberg DN, Zaltzman JS, Gill JS.

Transplant Res. 2013 Jan 12;2(1):1. doi: 10.1186/2047-1440-2-1.

30.

Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach.

Gadegbeku CA, Gipson DS, Holzman LB, Ojo AO, Song PX, Barisoni L, Sampson MG, Kopp JB, Lemley KV, Nelson PJ, Lienczewski CC, Adler SG, Appel GB, Cattran DC, Choi MJ, Contreras G, Dell KM, Fervenza FC, Gibson KL, Greenbaum LA, Hernandez JD, Hewitt SM, Hingorani SR, Hladunewich M, Hogan MC, Hogan SL, Kaskel FJ, Lieske JC, Meyers KE, Nachman PH, Nast CC, Neu AM, Reich HN, Sedor JR, Sethna CB, Trachtman H, Tuttle KR, Zhdanova O, Zilleruelo GE, Kretzler M.

Kidney Int. 2013 Apr;83(4):749-56. doi: 10.1038/ki.2012.428. Epub 2013 Jan 16.

31.

Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study.

Irazabal MV, Eirin A, Lieske J, Beck LH, Sethi S, Borland TM, Dillon JJ, Nachman PH, Nasr SH, Cornell LD, Leung N, Cattran DC, Fervenza FC.

Nephrol Dial Transplant. 2013 Jan;28(1):137-46. doi: 10.1093/ndt/gfs379. Epub 2012 Sep 17.

32.

The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines--application to the individual patient.

Radhakrishnan J, Cattran DC.

Kidney Int. 2012 Oct;82(8):840-56. doi: 10.1038/ki.2012.280. Epub 2012 Aug 15. Review.

33.

Is long-term prediction in membranous nephropathy (MGN) better than the weatherman's forecast capacity?

Cattran DC, Kim J.

Clin J Am Soc Nephrol. 2012 Aug;7(8):1203-5. doi: 10.2215/CJN.06600712. Epub 2012 Jul 19. No abstract available.

34.

Glomerular disease search filters for Pubmed, Ovid Medline, and Embase: a development and validation study.

Hildebrand AM, Iansavichus AV, Lee CW, Haynes RB, Wilczynski NL, McKibbon KA, Hladunewich MA, Clark WF, Cattran DC, Garg AX.

BMC Med Inform Decis Mak. 2012 Jun 6;12:49. doi: 10.1186/1472-6947-12-49.

35.

Rituximab therapy for Type I membranoproliferative glomerulonephritis.

Dillon JJ, Hladunewich M, Haley WE, Reich HN, Cattran DC, Fervenza FC.

Clin Nephrol. 2012 Apr;77(4):290-5.

PMID:
22445472
36.

Venous thromboembolism in patients with membranous nephropathy.

Lionaki S, Derebail VK, Hogan SL, Barbour S, Lee T, Hladunewich M, Greenwald A, Hu Y, Jennette CE, Jennette JC, Falk RJ, Cattran DC, Nachman PH, Reich HN.

Clin J Am Soc Nephrol. 2012 Jan;7(1):43-51. doi: 10.2215/CJN.04250511. Epub 2011 Nov 10.

37.

Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis.

Barbour SJ, Greenwald A, Djurdjev O, Levin A, Hladunewich MA, Nachman PH, Hogan SL, Cattran DC, Reich HN.

Kidney Int. 2012 Jan;81(2):190-5. doi: 10.1038/ki.2011.312. Epub 2011 Sep 14.

38.

Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy.

Beck LH Jr, Fervenza FC, Beck DM, Bonegio RG, Malik FA, Erickson SB, Cosio FG, Cattran DC, Salant DJ.

J Am Soc Nephrol. 2011 Aug;22(8):1543-50. doi: 10.1681/ASN.2010111125. Epub 2011 Jul 22.

39.

Historical aspects of proteinuria.

Cattran DC.

Adv Chronic Kidney Dis. 2011 Jul;18(4):224-32. doi: 10.1053/j.ackd.2011.06.008.

PMID:
21782128
40.

Have we changed the outcome in membranous nephropathy? A propensity study on the role of immunosuppressive therapy.

Cattran DC, Reich HN, Kim SJ, Troyanov S.

Clin J Am Soc Nephrol. 2011 Jul;6(7):1591-8. doi: 10.2215/CJN.11001210. Epub 2011 Jun 16.

41.

Validation of the Oxford classification of IgA nephropathy.

Herzenberg AM, Fogo AB, Reich HN, Troyanov S, Bavbek N, Massat AE, Hunley TE, Hladunewich MA, Julian BA, Fervenza FC, Cattran DC.

Kidney Int. 2011 Aug;80(3):310-7. doi: 10.1038/ki.2011.126. Epub 2011 May 4.

42.

Maintenance immunosuppression in antineutrophil cytoplasmic antibody-associated vasculitis.

Cattran DC, Hladunewich MA.

Am J Kidney Dis. 2011 Jun;57(6):818-21. doi: 10.1053/j.ajkd.2011.03.006. Epub 2011 Apr 19. No abstract available.

PMID:
21507537
43.

Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus.

Reich HN, Gladman DD, Urowitz MB, Bargman JM, Hladunewich MA, Lou W, Fan SC, Su J, Herzenberg AM, Cattran DC, Wither J, Landolt-Marticorena C, Scholey JW, Fortin PR.

Kidney Int. 2011 Apr;79(8):914-20. doi: 10.1038/ki.2010.525. Epub 2011 Jan 19.

44.

A molecular signature of proteinuria in glomerulonephritis.

Reich HN, Tritchler D, Cattran DC, Herzenberg AM, Eichinger F, Boucherot A, Henger A, Berthier CC, Nair V, Cohen CD, Scholey JW, Kretzler M.

PLoS One. 2010 Oct 18;5(10):e13451. doi: 10.1371/journal.pone.0013451.

45.

Delayed graft function and the risk of death with graft function in living donor kidney transplant recipients.

Narayanan R, Cardella CJ, Cattran DC, Cole EH, Tinckam KJ, Schiff J, Kim SJ.

Am J Kidney Dis. 2010 Nov;56(5):961-70. doi: 10.1053/j.ajkd.2010.06.024. Epub 2010 Sep 25.

PMID:
20870331
46.

Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.

Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U, Nachman PH, Bergstralh EJ, Leung N, Cosio FG, Hogan MC, Dillon JJ, Hickson LJ, Li X, Cattran DC; Mayo Nephrology Collaborative Group.

Clin J Am Soc Nephrol. 2010 Dec;5(12):2188-98. doi: 10.2215/CJN.05080610. Epub 2010 Aug 12.

47.

Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial.

House AA, Eliasziw M, Cattran DC, Churchill DN, Oliver MJ, Fine A, Dresser GK, Spence JD.

JAMA. 2010 Apr 28;303(16):1603-9. doi: 10.1001/jama.2010.490.

PMID:
20424250
48.

The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults.

Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Coppo R, Troyanov S, Camilla R, Hogg RJ, Cattran DC, Cook HT, Feehally J, Roberts IS, Amore A, Alpers CE, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D'Agati V, D'Amico G, Emancipator SN, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo AB, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Li LS, Li PK, Liu ZH, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H.

Kidney Int. 2010 May;77(10):921-7. doi: 10.1038/ki.2010.43. Epub 2010 Mar 3.

49.

Delayed graft function and the risk for death with a functioning graft.

Tapiawala SN, Tinckam KJ, Cardella CJ, Schiff J, Cattran DC, Cole EH, Kim SJ.

J Am Soc Nephrol. 2010 Jan;21(1):153-61. doi: 10.1681/ASN.2009040412. Epub 2009 Oct 29.

50.

The natural history of the non-nephrotic membranous nephropathy patient.

Hladunewich MA, Troyanov S, Calafati J, Cattran DC; Metropolitan Toronto Glomerulonephritis Registry.

Clin J Am Soc Nephrol. 2009 Sep;4(9):1417-22. doi: 10.2215/CJN.01330209. Epub 2009 Aug 6.

Supplemental Content

Loading ...
Support Center